Nervonik raised $52.5 million in a Series B round to support development and commercialization planning for its peripheral nerve stimulation (PNS) system aimed at chronic pain and other neurological conditions. The financing is earmarked for enhancements to sensing capabilities and continued clinical and regulatory readiness for market entry. The company’s continued emphasis on sensing upgrades suggests a focus on improving closed-loop behavior and patient outcomes rather than simply scaling hardware production. With chronic pain markets remaining crowded, differentiated sensing and signal control are often pivotal for demonstrating consistent efficacy. For investors, the round signals continued capital availability for neurotechnology platforms where clinical proof and workflow integration can justify commercialization milestones.